AI-generated summary
The authors ran a placebo-controlled randomized trial of low-level laser therapy (670 nm) in 20 patients with fibromyalgia, comparing treatment with a placebo group over 4 weeks. They report that symptom measures improved more in the laser group than in the placebo group, and they suggest further investigation is warranted.
- Participants
- 20
- Who or what was studied
- Patients with fibromyalgia
- Wavelengths
- 670 nm
- Limits stated in the abstract
- The abstract describes a small trial of 20 patients, split into two groups of 10, so the findings are based on limited numbers.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 670 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Fibromyalgia, Laser, Visual analogue scale, Placebo-controlled, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.